Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: | Tecentriq |
Active Ingredient: | Atezolizumab 840mg/14mL |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | Roche Products (NZ) Limited |
Manufacturers: | F Hoffmann-La Roche Limited, Kaiseraugst, Switzerland Genentech Inc, Oregon, United States of America |
Product: | Tecentriq |
Active Ingredient: | Atezolizumab 1200mg/20mL |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | Roche Products (NZ) Limited |
Manufacturers: | Roche Diagnostics GmbH, Mannheim, Germany F Hoffmann-La Roche Limited, Kaiseraugst, Switzerland Genentech Inc, Oregon, United States of America |
Dated this 26th day of February 2024.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).